Small bowel adenocarcinoma

Small bowel adenocarcinoma
Name	Small bowel adenocarcinoma

Small bowel adenocarcinoma is a rare malignant neoplasm arising from the glandular epithelium of the small intestine, most commonly the duodenum and proximal jejunum. First described in early surgical literature, it has been documented in case series from institutions such as Mayo Clinic, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, and Cleveland Clinic. Epidemiologic and clinical features have been reported by organizations including the World Health Organization, American Cancer Society, National Cancer Institute, and collaborative registries like the SEER Program.

Signs and symptoms

Patients typically present with non‑specific abdominal complaints documented in clinical reports from Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and case reviews in journals such as The Lancet, New England Journal of Medicine, Journal of Clinical Oncology, Annals of Surgery, and Gastroenterology. Common presentations include intermittent crampy abdominal pain, weight loss, nausea, vomiting, gastrointestinal bleeding, and obstructive symptoms, often leading to evaluation at centers like Mount Sinai Hospital, UCSF Medical Center, Stanford Hospital, UCLA Medical Center, and Brigham and Women’s Hospital. Advanced cases may exhibit palpable mass, jaundice when involving the ampulla of Vater (described in reports from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Royal Marsden Hospital, Great Ormond Street Hospital, and Karolinska University Hospital). Symptom overlap with conditions treated at Mayo Clinic and Johns Hopkins Hospital — including inflammatory, infectious, and ischemic disorders — often delays diagnosis.

Causes and risk factors

Epidemiologic associations reported by World Health Organization, National Cancer Institute, American Cancer Society, and cohorts from SEER Program indicate increased risk with hereditary syndromes and chronic inflammatory conditions. Notable risk factors include hereditary syndromes such as Lynch syndrome, Familial adenomatous polyposis, and Peutz–Jeghers syndrome reported in genetic studies affiliated with Harvard Medical School, University of Oxford, Cambridge University, University of Toronto, and University College London. Chronic enterohepatic and biliary exposures linked in case series from Mayo Clinic and Mount Sinai Hospital include celiac disease and Crohn’s disease, with data published in Gastroenterology, Gut, BMJ, The Lancet Oncology, and Clinical Gastroenterology and Hepatology. Environmental and lifestyle contributions have been explored in multi‑center studies led by National Institutes of Health, Centers for Disease Control and Prevention, European Cancer Organisation, International Agency for Research on Cancer, and national cancer registries in Japan, France, Germany, Sweden, and Australia.

Pathophysiology and molecular biology

Molecular profiling from laboratories at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Broad Institute, and Sanger Institute shows alterations similar to colorectal adenocarcinoma and distinct patterns influenced by tumor location. Recurrent mutations and pathways implicated include alterations in TP53 and mismatch repair genes associated with Lynch syndrome described in genetic reports from Harvard Medical School, University of Oxford, Johns Hopkins University, University of California, San Francisco, and Yale School of Medicine. KRAS, APC, and SMAD4 pathway aberrations have been documented in sequencing studies published in Nature, Science, Cell, Nature Genetics, and Genome Research with contributors from Broad Institute and Sanger Institute. Microsatellite instability, CpG island methylator phenotype, and tumor mutational burden have prognostic and therapeutic implications reported by American Society of Clinical Oncology, European Society for Medical Oncology, National Comprehensive Cancer Network, ASCO, and trial groups at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

Diagnosis

Diagnosis is established through endoscopic, radiologic, histopathologic, and molecular methods. Upper endoscopy, enteroscopy, capsule endoscopy, and double‑balloon enteroscopy — techniques refined at Mayo Clinic, Johns Hopkins Hospital, UCSF Medical Center, Vanderbilt University Medical Center, and Royal Free Hospital — permit visualization and biopsy. Cross‑sectional imaging with CT enterography, MRI enterography, and PET/CT are commonly performed at Massachusetts General Hospital, Mount Sinai Hospital, Karolinska University Hospital, Hôpital Européen Georges-Pompidou, and Charité – Universitätsmedizin Berlin. Pathologic evaluation by specialist laboratories at Mayo Clinic, Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, Guy’s and St Thomas’ NHS Foundation Trust, and academic centers uses immunohistochemistry panels and molecular assays described in consensus guidelines from NCCN, ESMO, ASCO, and WHO.

Treatment

Multimodal management strategies are based on surgical oncology, medical oncology, and radiation oncology protocols developed at institutions like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Mayo Clinic, Johns Hopkins Hospital, and Royal Marsden Hospital. Curative intent involves segmental resection, pancreaticoduodenectomy for periampullary tumors, and lymphadenectomy as recommended in guidelines from NCCN, ESMO, ASCO, Society of Surgical Oncology, and American College of Surgeons. Systemic chemotherapy regimens adapted from colorectal protocols — including combinations studied in trials led by EORTC, SWOG, Alliance for Clinical Trials in Oncology, NCIC Clinical Trials Group, and Gastrointestinal Oncology Group — use fluoropyrimidines, oxaliplatin, and irinotecan; targeted therapies and immune checkpoint inhibitors informed by trials at MD Anderson Cancer Center, Dana-Farber Cancer Institute, Broad Institute, and Memorial Sloan Kettering Cancer Center are used for biomarker‑selected patients. Palliative radiation and endoscopic stenting for obstruction are provided at tertiary centers such as Mayo Clinic, UCLA Medical Center, UCSF Medical Center, Mount Sinai Hospital, and Stanford Hospital.

Prognosis and epidemiology

Prognosis varies by stage, location, histologic grade, and molecular features; outcomes and survival statistics are reported by SEER Program, National Cancer Institute, American Cancer Society, European Cancer Observatory, and institutional series from Mayo Clinic, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Johns Hopkins Hospital, and Massachusetts General Hospital. Incidence is low relative to colorectal and gastric cancers, with geographic variation described in datasets from Japan, France, United Kingdom, United States, Sweden, and Australia. Five‑year survival rates decline with advanced stage and nodal involvement, as summarized in reviews published in The Lancet Oncology, Journal of Clinical Oncology, Gastroenterology, Annals of Oncology, and consensus statements from ESMO and NCCN.

Category:Gastrointestinal cancer